surveillance and solutions. Biochem Med (Zagreb). 2020 Jun 15;30(2):020502. \[[PMC free article: PMC7271754](/pmc/articles/PMC7271754/)\] \[[PubMed: 32550813](https://pubmed.ncbi.nlm.nih.gov/32550813)\] 39. Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem. 2011 Dec;57(12):1670-80. \[[PubMed: 21965556](https://pubmed.ncbi.nlm.nih.gov/21965556)\] 40. Delatour V, Clouet-Foraison N, Jaisson S, Kaiser P, Gillery P. Trueness assessment of HbA1c routine assays: are processed EQA materials up to the job? Clin Chem Lab Med. 2019 Sep 25;57(10):1623-1631. \[[PubMed: 31085744](https://pubmed.ncbi.nlm.nih.gov/31085744)\] 41. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM., National Academy of Clinical Biochemistry. Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun;34(6):e61-99. \[[PMC free article: PMC3114322](/pmc/articles/PMC3114322/)\] \[[PubMed: 21617108](https://pubmed.ncbi.nlm.nih.gov/21617108)\] 42. Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B, Tikka C, Ruotsalainen JH, Kilinc Balci FS. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database Syst Rev. 2020 May 15;5(5):CD011621. \[[PMC free article: PMC8785899](/pmc/articles/PMC8785899/)\] \[[PubMed: 32412096](https://pubmed.ncbi.nlm.nih.gov/32412096)\] 43. Saboo B, Kesavadev J, Shankar A, Krishna MB, Sheth S, Patel V, Krishnan G. Time-in-range as a target in type 2 diabetes: An urgent need. Heliyon. 2021 Jan;7(1):e05967. \[[PMC free article: PMC7814148](/pmc/articles/PMC7814148/)\] \[[PubMed: 33506132](https://pubmed.ncbi.nlm.nih.gov/33506132)\] **Disclosure:** Emily Eyth declares no relevant financial relationships with ineligible companies. **Disclosure:** Muhammad Zubair declares no relevant financial relationships with ineligible companies. **Disclosure:** Roopa Naik declares no relevant financial relationships with ineligible companies.